DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20192178

Evaluation of voglibose on body weight in rats

Sarita Mulkalwar, Tanya Gupta, Vishwanath Kulkarni, A. V. Tilak, B. T. Rane, Anita Barde

Abstract


Background: As of 2018, 2.1 billion people nearly 30% of the world’s population are either obese or overweight. Worldwide obesity has nearly tripled since 1975. It is an emerging health problem with major adverse effects on health. It is a risk factor for many chronic diseases but is best known for its role in metabolic syndrome, which can lead to type 2 diabetes mellitus as well as cardiovascular diseases. Anti-obesity drugs are available but have many side effects. Voglibose, an antidiabetic drug, is an alpha glucosidase inhibitor which shows promising results in the reduction of body weight with minimal side effects.

Methods: Voglibose (7 mg/kg) was administered to rats fed with normal laboratory chows and high fat diet to see its effect on body weight, body mass index, abdominal and thoracic circumference, and lipid profile at the end of 12 weeks.

Results: Administration of voglibose significantly reduced food consumption, feed efficiency and increase in body weight induced by high fat diet in rats. Rats fed on normal diet also showed reductions in the same parameters, suggesting its weight lowering effect. Reductions in the anthropometric measurements, hypolipidemic effects and glucose lowering effects were also observed.

Conclusions: Voglibose prevented high fat diet-induced obesity and improvement in metabolic profile, which ultimately has systemic effects on body weight in rats. Further studies are needed to see its potential therapeutic use in obese patients with type 2 diabetes mellitus, and related complications.


Keywords


Body weight, High fat diet, Metabolic syndrome, Voglibose

Full Text:

PDF

References


Fausi AS, Kasper DL. Harrison’s Principles of Internal Medicine. 18th ed. New York; McGraw-Hill Medical Publishing division. 2010;622-635.

WHO Obesity and overweight. world health organisation [internet]. 2015 [cited 2016 June 15]. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/

Cho NH, Whiting D, Forouhi N. IDF Diabetes Atlas [e-book]. 7th ed. Brussels (Bel): International Diabetes Federation; 2015 [cited 2016 Jun 09]. Available at: http://www.idf.org/diabetesatlas.

Matsumoto K, Yano M, Miyake S. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients, Diabetes Care. 1998 Feb 1;21(2):256-60.

Van de Laar FA, Lucassen PL, Akkermans RP et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis, Diabetes Care. 2005 Jan 1;28(1):154-63.

Kumar RV, Sinha VR. Newer insights into the drug delivery approaches of aglucosidase inhibitors, Expert Opin. Drug Deliv. 2012 Apr 1;9(4):403-16.

Standl E, Schnell O. Alpha-glucosidase inhibitors, cardiovascular considerations and trial evaluation, Diab. Vasc. Dis. Res. 2012 Jul;9(3):163-9.

Do JH, Lee YS, Ha MJ et al. Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification. Endocrine J. 2016;63(8):691-702.

Moritoh Y, Takeuchi K and Hazama M. Chronic Administration of Voglibose, an α-Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob Mice. J Pharmacol Experim Therapeu. JPET 2009 May 1;329(2):669-76.

Jones RB, Vickers SP, Cheetham SC et al. Effect of linagliptin,alone and in combination with voglibose or exendin-4,on glucose control in male ZDF rats. Eur J Pharmacol. 2014 Apr 15;729:59-66.

Fujitaka K, Otani H, Jo F et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocr J. 2011;58(6):425-32.

Negishi M, Shimomura K, Proks P. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients. Br J Clin Pharmacol. 2008 Aug 1;66(2):318-9.

Do HJ, Jin T, Chung JH et al. Voglibose administration regulates body weight and energy intake in high fat-induced obese mice. Biochem Biophys Res Commun. 2014 Jan 17;443(3):1110-7.

Naik ME, Palit R, Agrawal D, Rath K, Kumar S, Mishra SS. Effect of voglibose on lipid profile in alloxan-induced diabetic rabbits with type-ii diabetes mellitus and dyslipidemia. Int J Pharm Bio Sci. 2014 July;5(3):259-67.

Yasuda K, Shimowada K, Uno M et al. Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats. Diabetes Res Clin Pract. 2003 Feb 1;59(2):113-22.

Vichayanrat A et al. Alpha glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract. 2002;55(2):99-103.